Autonomic Nervous System Drugs Practice Questions

Q: Which of the following is NOT a function of H1 antagonists?

Decrease gastric acid secretion. The correct answer is **C (Decrease gastric acid secretion)** because this function is mediated by **H2 receptors**, not H1 receptors [2]. Histamine acts on different receptor subtypes: * **H1 Receptors:** Located in smooth muscles, endothelium, and the CNS. They mediate allergic inflammation, pruritus, and wakefulness [1], [3]. * **H2 Receptors:** Located primarily on the **gastric parietal cells**. Activation increases cAMP, leading to gastric acid secretion. Therefore, H2 antagonists (e.g., Ranitidine, Famotidine) are used to decrease acid, while H1 antagonists have no effect on this process [2]. **Analysis of other options:** * **A. Antipruritic:** H1 receptors mediate the "itch" sensation in sensory nerve endings. H1 blockers are the mainstay for treating urticaria and allergic pruritus [2], [3]. * **B. Sedation:** First-generation H1 blockers (e.g., Diphenhydramine, Chlorpheniramine) are highly lipophilic and cross the blood-brain barrier. By blocking central H1 receptors involved in arousal, they cause significant sedation [4]. * **D. Antivertigo:** Certain H1 antagonists (e.g., Cinnarizine, Meclizine, Promethazine) have significant anticholinergic and central effects that suppress the vestibular apparatus, making them effective for motion sickness and vertigo. **NEET-PG High-Yield Pearls:** 1. **Second-generation H1 blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are non-sedating because they have poor CNS penetration and are substrates for the P-glycoprotein efflux pump [1], [4]. 2. **Fexofenadine** is the active metabolite of Terfenadine and is considered the least sedating [1]. 3. **Astemizole and Terfenadine** were withdrawn due to the risk of **Torsades de Pointes** (QT prolongation) when co-administered with CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin).

Q: Which of the following drugs does NOT act on dopamine receptors?

Dobutamine. **Explanation:** The correct answer is **Dobutamine** because it is a synthetic catecholamine that acts primarily as a **selective $\beta_1$-adrenergic agonist**. While it has minor activity at $\beta_2$ and $\alpha_1$ receptors, it possesses **no significant affinity for dopamine (D) receptors**. It is clinically used as an inotrope in cardiogenic shock and for stress echocardiography. **Analysis of Options:** * **Dopamine:** An endogenous catecholamine that acts in a dose-dependent manner [2]. At low doses, it stimulates **$D_1$ receptors** (renal vasodilation); at medium doses, $\beta_1$ receptors (inotropy); and at high doses, $\alpha_1$ receptors (vasoconstriction) [1]. * **Fenoldopam:** A selective **$D_1$ receptor agonist**. It causes systemic vasodilation and is specifically used in the management of hypertensive emergencies, particularly when renal perfusion needs to be maintained. * **Haloperidol:** A typical antipsychotic that functions as a potent **$D_2$ receptor antagonist** in the mesolimbic and nigrostriatal pathways. **High-Yield Clinical Pearls for NEET-PG:** * **Dobutamine vs. Dopamine:** Dobutamine is preferred in acute heart failure because it increases cardiac output with less increase in heart rate and lower risk of arrhythmias compared to dopamine. * **Fenoldopam:** It is the only intravenous antihypertensive that improves renal perfusion (natriuretic and diuretic properties). * **D1 Receptors:** Gs-protein coupled; they increase cAMP and cause smooth muscle relaxation (vasodilation) [2]. * **D2 Receptors:** Gi-protein coupled; they inhibit adenylyl cyclase and are the primary targets for most antipsychotic drugs.

Q: Which cholinergic receptor is the primary target for drugs used to treat urinary incontinence in neurogenic bladder?

M3. ### Explanation **Correct Option: C (M3)** The primary goal in treating urinary incontinence (specifically urge incontinence or overactive bladder) is to reduce the involuntary contractions of the **detrusor muscle**. * **Mechanism:** The detrusor muscle contains both M2 and M3 receptors. However, the **M3 receptor** is the functionally dominant subtype responsible for bladder contraction [1]. * **Action:** Activation of M3 receptors (via Gq protein) leads to increased intracellular calcium, causing detrusor contraction and bladder emptying. Therefore, **M3 antagonists** (e.g., Oxybutynin, Darifenacin, Solifenacin) are used to promote bladder relaxation and increase storage capacity [1], [2]. **Incorrect Options:** * **A (M1):** These receptors are primarily located in the CNS and gastric parietal cells [3]. They are involved in memory and gastric acid secretion, not bladder contraction. * **B (M2):** While M2 receptors are numerically more abundant in the bladder than M3, they primarily function by inhibiting adenylate cyclase (Gi). Their role in direct contraction is secondary to M3; they mainly counteract sympathetically mediated relaxation [1]. * **D (M4):** These are primarily found in the CNS (striatum) and are involved in modulating locomotor activity and dopamine release, with no significant role in bladder dynamics. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** **Oxybutynin** is a classic non-selective muscarinic antagonist, while **Darifenacin** and **Solifenacin** are M3-selective, offering fewer systemic side effects (like dry mouth/xerostomia) [1], [2]. * **Mirabegron:** A newer alternative for overactive bladder that acts as a **β3-agonist**, promoting bladder relaxation. * **Contraindication:** Antimuscarinics should be avoided in patients with **narrow-angle glaucoma** and **benign prostatic hyperplasia (BPH)** due to the risk of acute urinary retention.

Q: Which of the following is the most uroselective anticholinergic drug?

Darifenacin. **Explanation:** **Darifenacin** is the correct answer because it is a highly selective **M3 receptor antagonist**. The M3 muscarinic receptors are primarily responsible for bladder detrusor muscle contraction. By selectively blocking these receptors, Darifenacin reduces bladder overactivity with a lower incidence of systemic side effects (like dry mouth or blurred vision) compared to non-selective agents like Oxybutynin. It is specifically indicated for Overactive Bladder (OAB). **Analysis of Incorrect Options:** * **Tolbutamide:** This is a **First-generation Sulfonylurea** used in the management of Type 2 Diabetes Mellitus. It acts by stimulating insulin release from pancreatic beta cells and has no anticholinergic properties. * **Duloxetine:** This is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**. While it is used in the treatment of Stress Urinary Incontinence (SUI) by increasing the tone of the external urethral sphincter via Onuf’s nucleus, it is not an anticholinergic. * **Tamsulosin:** This is a **selective Alpha-1A blocker**. It is used in Benign Prostatic Hyperplasia (BPH) to relax the smooth muscles of the bladder neck and prostate. It is "uroselective" for alpha receptors, but it is not an anticholinergic drug. **High-Yield Clinical Pearls for NEET-PG:** * **M3 Selective Anticholinergics:** Darifenacin and Solifenacin (Mnemonic: **D**ari-**S**oli are **M3** holy). * **Non-selective Anticholinergics for OAB:** Oxybutynin, Tolterodine, Trospium, and Fesoterodine. * **Mirabegron:** A Beta-3 agonist used for OAB; it is a preferred alternative if anticholinergics are contraindicated (e.g., in narrow-angle glaucoma). * **Drug of choice for Enuresis:** Desmopressin (Non-pharmacological: Bed-wetting alarms).

Q: Organophosphates bind to which site of acetylcholinesterase?

Esteratic site. ### Explanation **Mechanism of Action:** Acetylcholinesterase (AChE) is the enzyme responsible for the hydrolysis of acetylcholine (ACh). It possesses two primary functional domains: the **Anionic site** (which attracts the positive quaternary ammonium group of ACh) and the **Esteratic site** (which contains a serine residue responsible for the actual cleavage of the ester bond). **Organophosphates (OPs)** are irreversible inhibitors that function by phosphorylating the serine hydroxyl group at the **Esteratic site**. This creates a stable covalent bond that prevents the enzyme from breaking down acetylcholine, leading to a "cholinergic crisis." **Analysis of Options:** * **Option A (Anionic site):** This site primarily binds the choline moiety of ACh. Drugs like **Edrophonium** (a reversible anticholinesterase) bind non-covalently to the anionic site. OPs do not bind here. * **Option B (Esteratic site):** Correct. OPs form a covalent phosphate-enzyme complex at this site. * **Option C (Acetylcholine):** This is the endogenous substrate, not a binding site on the enzyme itself. **Clinical Pearls for NEET-PG:** 1. **Aging:** Over time, the OP-enzyme bond strengthens (loss of an alkyl group), making it irreversible. This process is called "Aging." 2. **Pralidoxime (2-PAM):** Known as a "Cholinesterase Reactivator," it can break the OP-enzyme bond, but **only before aging occurs**. It works by displacing the phosphate group from the esteratic site. 3. **Atropine:** The specific antidote for the muscarinic effects of OP poisoning; it does not reactivate the enzyme but blocks the excess ACh at the receptor level. 4. **Carbamates vs. OPs:** Carbamates (like Neostigmine) also bind to the esteratic site but are reversible and do not undergo "aging."

Q: What is the primary site of action for vecuronium?

Neuromuscular junction. **Explanation:** **Vecuronium** is a non-depolarizing skeletal muscle relaxant belonging to the aminosteroid group. Its primary site of action is the **Neuromuscular Junction (NMJ)**. 1. **Why Option D is Correct:** Vecuronium acts as a competitive antagonist at the **nicotinic acetylcholine receptors (Nm)** located on the motor endplate of the NMJ. By binding to these receptors, it prevents acetylcholine (ACh) from binding, thereby inhibiting endplate potential and preventing muscle contraction. This results in flaccid paralysis of skeletal muscles. 2. **Why Other Options are Incorrect:** * **Options A & B (Cerebrum & Reticular Formation):** Vecuronium is a quaternary ammonium compound, making it highly polar and lipid-insoluble. Consequently, it **cannot cross the blood-brain barrier (BBB)** and has no effect on the Central Nervous System (CNS). It does not cause sedation or anesthesia. * **Option C (Motor Neuron):** Vecuronium does not interfere with the conduction of the action potential along the motor nerve or the release of ACh from the pre-synaptic terminal; its action is strictly post-synaptic at the receptor level. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** Vecuronium is primarily excreted via **bile** (60-80%) and secondarily by the kidneys. It is often preferred in patients with compensated renal failure compared to pancuronium. * **Cardiovascular Stability:** Unlike tubocurarine (histamine release) or pancuronium (tachycardia), vecuronium is known for its **cardiovascular stability**, making it ideal for cardiac surgeries. * **Reversal:** Its effects can be reversed using acetylcholinesterase inhibitors like **Neostigmine** (co-administered with glycopyrrolate) or the specific chelating agent **Sugammadex**.

Q: What is the primary location of alpha-1 adrenergic receptors?

Blood vessels. **Explanation:** **Alpha-1 ($\alpha_1$) adrenergic receptors** are G-protein coupled receptors (linked to the $G_q$ pathway) primarily located on **vascular smooth muscle**. When stimulated by norepinephrine or epinephrine, they increase intracellular calcium, leading to smooth muscle contraction. This results in **vasoconstriction**, which increases peripheral vascular resistance and raises blood pressure. **Analysis of Options:** * **A. Blood vessels (Correct):** This is the predominant site. $\alpha_1$ receptors are found in the skin, splanchnic circulation, and mucous membranes. * **B. Bronchi:** The primary receptors in the bronchial smooth muscle are **$\beta_2$ receptors**, which mediate bronchodilation. $\alpha_1$ receptors have a negligible effect on airway caliber. * **C. Sweat glands:** Most sweat glands (eccrine) are regulated by **muscarinic (M) receptors** via sympathetic cholinergic fibers. Only localized "stress" sweating (apocrine) involves $\alpha$ receptors. * **D. Heart:** The heart is dominated by **$\beta_1$ receptors**, which increase heart rate and contractility. While some $\alpha_1$ receptors exist in the myocardium, their clinical significance is minimal compared to $\beta_1$. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mydriasis:** $\alpha_1$ receptors are also located on the **radial muscle of the iris**; stimulation causes pupillary dilation (mydriasis) without cycloplegia. 2. **Sphincters:** $\alpha_1$ stimulation causes contraction of the internal urethral sphincter and prostate, which is why $\alpha_1$-blockers (e.g., Tamsulosin) are used in **Benign Prostatic Hyperplasia (BPH)**. 3. **Signal Transduction:** Remember the mnemonic **"QISS"** for $\alpha_1, \alpha_2, \beta_1, \beta_2$ ($\alpha_1$ is $G_q$ $\rightarrow$ IP3/DAG pathway).

Q: All of the following are anticholinergics, except?

Amphetamine. ### Explanation **Correct Answer: D. Amphetamine** **1. Why Amphetamine is the Correct Answer:** Amphetamine is a **sympathomimetic** (indirect-acting adrenergic agonist), not an anticholinergic. It works by stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals and inhibiting their reuptake. Its effects mimic the activation of the sympathetic nervous system (tachycardia, hypertension, mydriasis), which can sometimes be confused with anticholinergic effects, but its mechanism of action is entirely different. **2. Why the Other Options are Incorrect:** * **A. Ipratropium bromide:** A synthetic quaternary ammonium compound that acts as a **muscarinic antagonist**. It is used via inhalation for COPD and asthma to cause bronchodilation. * **B. Dicyclomine:** A tertiary amine with **antimuscarinic** properties. It is primarily used as an antispasmodic in Irritable Bowel Syndrome (IBS) to reduce GI motility. * **C. Atropine:** The **prototype anticholinergic** drug. It is a naturally occurring belladonna alkaloid that competitively blocks muscarinic receptors ($M_1, M_2, M_3$). **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Anticholinergic Toxidrome Mnemonic:** "Hot as a hare (hyperthermia), Red as a beet (flushing), Dry as a bone (anhidrosis), Blind as a bat (mydriasis/cycloplegia), Mad as a hatter (delirium)." * **Quaternary vs. Tertiary Amines:** Ipratropium and Tiotropium are quaternary (highly polar), meaning they do not cross the blood-brain barrier (BBB) and have minimal systemic side effects. Atropine and Dicyclomine are tertiary amines and can cross the BBB. * **Drug of Choice (DOC):** Atropine is the DOC for **symptomatic bradycardia** and **organophosphate poisoning**. * **Amphetamine Use:** Clinically used for ADHD and Narcolepsy, but carries a high risk of abuse and "pounding" cardiovascular side effects.

Question 1

Which of the following is NOT a function of H1 antagonists?

Accepted Answer

Decrease gastric acid secretion

Answer

Antipruritic

Answer

Sedation

Answer

Antiveigo

Question 2

A patient presented in the emergency with tachycardia, hyperthermia, bronchial dilation, and constipation. The person is likely to be suffering from an overdose of:

Accepted Answer

Atropine

Answer

Organophosphorus compound

Answer

Mushroom

Answer

Paracetamol

Question 3

Which of the following drugs does NOT act on dopamine receptors?

Accepted Answer

Dobutamine

Answer

Dopamine

Answer

Fenoldopam

Answer

Haloperidol

Question 4

Which cholinergic receptor is the primary target for drugs used to treat urinary incontinence in neurogenic bladder?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

M4

Question 5

Which of the following is the most uroselective anticholinergic drug?

Accepted Answer

Darifenacin

Answer

Tolbutamide

Answer

Duloxetine

Answer

Tamsulosin

Question 6

Organophosphates bind to which site of acetylcholinesterase?

Accepted Answer

Esteratic site

Answer

Anionic site

Answer

Acetylcholine

Answer

None of the above

Question 7

What is the primary site of action for vecuronium?

Accepted Answer

Neuromuscular junction

Answer

Cerebrum

Answer

Reticular formation

Answer

Motor neuron

Question 8

Which of the following adverse effects limits the use of adrenoceptor blockers?

Accepted Answer

Heart failure exacerbation from beta blockers

Answer

Bronchoconstriction from alpha blocking agents

Answer

Impaired blood sugar response with alpha blockers

Answer

Increased intraocular pressure with beta blockers

Question 9

What is the primary location of alpha-1 adrenergic receptors?

Accepted Answer

Blood vessels

Answer

Bronchi

Answer

Sweat glands

Answer

Heart

Question 10

All of the following are anticholinergics, except?

Accepted Answer

Amphetamine

Answer

Ipratropium bromide

Answer

Dicyclomine

Answer

Atropine

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?